$55.94
1.142.08%
At close: -
$59.06
3.125.58%
After Hours: 6:44 PM EDT
Halozyme Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Halozyme Therapeutics using advanced sorting and filters.
Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Q3 | 2024-10-31 | $1.27 | $0.98 | 29.6 % |
Q2 | 2024-08-06 | $0.91 | $0.78 | 16.7 % |
Q1 | 2024-05-07 | $0.79 | $0.69 | 14.5 % |
Q4 | 2024-02-20 | $0.82 | $0.83 | -1.20 % |
Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Q3 | 2024-10-31 | $290.08M | $251.06M | 15.5 % |
Q2 | 2024-08-06 | $231.35M | $208.94M | 10.7 % |
Q1 | 2024-05-07 | $195.88M | $199.78M | -1.95 % |
Q4 | 2024-02-20 | $230.04M | $233.19M | -1.35 % |
Halozyme Therapeutics (HALO) is scheduled to report earnings on February 18, 2025. The last reported earnings were for reported on October 31, 2024 for Q3.
The Actual EPS was $1.27, which beat the estimate of $0.98.
The Actual Revenue was $290.1M, which beat the estimate of $251.1M.
Browse earnings estimates, EPS, and revenue on all stocks.